ARIAD Pharma (NASDAQ: ARIA) reported Q3 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $34.3 million versus the consensus estimate of $42.93 million.

ARIAD Pharma reaffirmed FY2016 guidance.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.